Invokana® (canagliflozin) – New indication
October 30, 2018 - Janssen and Johnson & Johnson announced the FDA approval of Invokana (canagliflozin), to reduce the risk of major adverse cardiovascular events (MACE) (cardiovascular death, nonfatal myocardial infarction [MI] and nonfatal stroke) in adults with type 2 diabetes mellitus (T2DM) and established cardiovascular disease (CVD).
Top